Priya Kosana

Priya Kosana

Auto-generated profile, based on publicly available information

Priya Kosana

Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2023 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
PKPriya Kosana
Priya Kosana
KWKunling Wu
Kunling Wu
KTKatherine Tassiopoulos
Katherine Tassiopoulos
SLScott Letendre
Scott Letendre
QMQing Ma
Qing Ma
SFShelli F Farhadian
Shelli F Farhadian
Background: Older people with human immunodeficiency virus (HIV, PWH) are prone to using multiple medications due to higher rates of medical comorbidities and the use of antiretroviral therapy (ART). We assessed the prevalence and clinical impact of polypharmacy among PWH. Methods: We leveraged clinical data from the AIDS Clinical Trials Group A5322 study “Long-Term Follow-up of Older HIV-infected Adults: Addressing Issues of Aging, HIV Infection and Inflammation” (HAILO). We included PWH aged ≥40 years with plasma HIV RNA levels <200 copies/µL. We assessed the relationship between polypharmacy (defined as the use of 5 or more prescription medications, excluding ART) and hyperpolypharmacy (defined as the use of 10 or more prescription medications, excluding ART) with slow gait speed (less than 1 meter/second) and falls, including recurrent falls. Results: Excluding ART, 24% of study participants had polypharmacy and 4% had hyperpolypharmacy. Polypharmacy was more common in women (30%) than men (23%). Participants with polypharmacy had a higher risk of slow gait speed (odds ratio [OR] = 1.78; 95% confidence interval [CI] = 1.27–2.50) and increased risk of recurrent falls (OR = 2.12; 95% CI = 1.06–4.23). The risk for recurrent falls was further increased in those with hyperpolypharmacy compared with those without polypharmacy (OR = 3.46; 95% CI = 1.32–9.12). Conclusions: In this large, mixed-sex cohort of PWH aged ≥40 years, polypharmacy was associated with slow gait speed and recurrent falls, even after accounting for medical comorbidities, alcohol use, substance use, and other factors. These results highlight the need for increased focus on identifying and managing polypharmacy and hyperpolypharmacy in PWH.

31 August 2023 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
FTFanny Fong-Yi Tang
Fanny Fong-Yi Tang
PKPriya Kosana
Priya Kosana
MJMark Jit
Mark Jit
FTFern Terris-Prestholt
Fern Terris-Prestholt
DWDan Wu
Dan Wu
JTJoseph D. Tucker
Joseph D. Tucker
A quasi-experimental study was conducted to evaluate the effectiveness of a pay-it-forward strategy for increasing influenza vaccination among children and older adults compared to a self-paid vaccination strategy in China. Pay-it-forward is an innovative community-engaged intervention in which participants receive a free influenza vaccination and are then asked if they would like to donate or create a message to support subsequent vaccinations. This economic evaluation used a decision-tree model to compare pay-it-forward to a standard of care arm in which patients had to pay for their own influenza vaccine. The analysis was performed from the healthcare provider perspective and costs were calculated with 2020 United States dollars. The time horizon was one year. In the base case analysis, pay-it-forward was more effective (111 vs 55 people vaccinated) but more costly than standard-of-care ($4477 vs $2725). Pay-it-forward spurred 96.4% (107/111) of individuals to voluntarily donate to support influenza vaccination for high-risk groups in China. Further costing and implementation research is needed to inform scale up.

6 July 2021
Verified
Conference Paper
Open access
PDF file
LCLinda Campbell
Linda Campbell
JTJ Tucker
J Tucker
AGAmanda Gabster
Amanda Gabster
SSSimukai Shamu
Simukai Shamu
KMK Mark
K Mark
PKP Kosana
P Kosana
Background Shelter-in-place and related COVID-19 physical distancing measures may influence the risk of intimate partner violence (IPV). The current study aims to (1) describe perceived changes in IPV experienced during and prior to the COVID-19 outbreak, (2) identify social correlates of IPV. Methods The International Sexual Health and REproductive Health (I-SHARE) study collected data on sexual and reproductive health during the COVID-19 pandemic (10,717 respondents in 16 countries between July 26thand December 1st 2020). The sample comprises participants in 7 HICs, 5 UMICs, 2 LMICs, and 2 LICs: 6,643 (62.3%) participants identified as women, 3,650 (34.2%) as men, and 178 (1.7%) as another gender. The median age was 30 (IQR 24; 39). Adults (≥18yrs) were recruited online (social media, panel, or population-representative). IPV was a primary outcome measured using an adapted six-item version of the WHO IPV scale. Mixed effects modelling was used to assess participants’ experience of IPV in the three months prior to, and during, the COVID-19 physical distancing measures; participants were also asked about informal and formal reporting of IPV. Results Preliminary analysis indicated that 1,864 (17.4%) of the 10,717 participants reported experiencing at least one form of IPV before the introduction of COVID-19 control measures; 1,346 (12.6%) participants reported IPV during COVID-19 physical distancing measures. Among participants experiencing IPV when physical distancing measures were in place, 691 (37.1%) told either a friend, the police, social services or other organization. Participants with a reduction in household income during the COVID-19 measures (aOR 1.48, 95% CI 1.29–1.69) and increased consumption of alcohol during COVID-19 (aOR 1.51, 95% CI 1.26–1.81) had higher odds of experiencing IPV. Conclusion IPV may have decreased during COVID-19 measures, but remained common overall. Structural interventions are necessary to mitigate the impact of IPV.

13 November 2026 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
PKPriya Kosana
Priya Kosana
AGAllison Grubman
Allison Grubman
GSGloria Shen
Gloria Shen
KWKunling Wu
Kunling Wu
KTKatherine Tassiopoulos
Katherine Tassiopoulos
SFShelli F. Farhadian
Shelli F. Farhadian
Background: People with HIV (PWH) are living longer because of effective antiretroviral therapy but face accelerated aging, accumulating comorbidities, and high rates of polypharmacy. Whether neuroinflammatory biomarkers are associated with polypharmacy and adverse clinical outcomes such as falls in this population is unknown. Methods: We performed a cross-sectional analysis of baseline data from 600 virally suppressed PWH ≥ 40 years enrolled in the ACTG A5322 HAILO cohort. Plasma neurofilament light chain (NfL), neopterin, and soluble CD14 (sCD14) were measured. Multivariable logistic regression examined associations between each biomarker and polypharmacy (5 or more non–antiretroviral therapy medications), recurrent falls (2 or more falls/6 mo), and slow gait speed less than 1 m/s, adjusting for age, sex, and comorbidity burden. Results: The median age was 54 years, 78% of participants were male, and 232 participants (39%) had polypharmacy. Elevated NfL was independently associated with polypharmacy in multivariable analysis [adjusted odds ratio: 1.16 (95% confidence interval: 1.07–1.26)]. In the total population, elevated NfL [odds ratio (OR): 1.24 (1.05–1.46)] and sCD14 [OR: 1.12 (1.01–1.23)] were each associated with recurrent falls. Among participants with polypharmacy, only elevated sCD14 remained associated with recurrent falls on stratified multivariable analysis [OR: 1.15 (1.02–1.30)]. No biomarker was significantly associated with slow gait speed. Conclusions: In older virally suppressed PWH, plasma NfL and sCD14 are associated with distinct adverse clinical phenotypes—medication burden and fall risk, respectively, and may serve as complementary biomarkers of distinct biological pathways relevant to aging in HIV.